Almitan 6.25 mg (Tablet)

Indications

• Acute headache phase of migraine attacks with or without aura
• Treatment of migraine in adolescents 12-17 years of age

Pharmacology

• Selective serotonin (5-hydroxytryptamine 1B/1D) agonist
• Binds to specific serotonin receptors on meningeal arteries
• Inhibits release of vasoactive peptides
• Causes constriction of arteries

Dosage & Administration

• Recommended dose of 6.25 mg to 12.5 mg for adults and adolescents
• Higher effectiveness of 12.5 mg dose in adults
• Maximum daily dose should not exceed 25 mg
• Recommended starting dose for hepatic impairment: 6.25 mg
• Maximum daily dose for hepatic impairment should not exceed 12.5 mg
• Recommended starting dose for severe renal impairment: 6.25 mg
• Maximum daily dose for severe renal impairment should not exceed 12.5 mg

Interaction

• Prolonged vasospastic reactions
• Risk of serotonin syndrome with SSRIs or SNRIs

Contraindications

• Ischaemic heart disease
• Severe hypertension
• Uncontrolled mild or moderate hypertension
• Concomitant administration with ergotamine or its derivatives
• Concomitant administration with other 5-HT1B/1D agonists

Side Effects

• Serious cardiac reactions, including myocardial infarction

Pregnancy & Lactation

• Pregnancy Category C
• No data on excretion in human milk

Precautions & Warnings

• Hypersensitivity to the active substance or excipients
• Severe hepatic impairment
• Previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA)
• Peripheral vascular disease

Therapeutic Class

• 5-HT Agonists

Storage Conditions

• Keep below 30°C
• Store in a dry place
• Protect from light
• Do not freeze
• Keep out of the reach of children

Related Brands